MX2017014544A - Tratamientos del cáncer. - Google Patents

Tratamientos del cáncer.

Info

Publication number
MX2017014544A
MX2017014544A MX2017014544A MX2017014544A MX2017014544A MX 2017014544 A MX2017014544 A MX 2017014544A MX 2017014544 A MX2017014544 A MX 2017014544A MX 2017014544 A MX2017014544 A MX 2017014544A MX 2017014544 A MX2017014544 A MX 2017014544A
Authority
MX
Mexico
Prior art keywords
cancer
treatment
stem cells
nuc
gemcitabine
Prior art date
Application number
MX2017014544A
Other languages
English (en)
Other versions
MX374946B (es
Inventor
Griffith Hugh
Mcguigan Chris
Pepper Chris
Original Assignee
NuCana plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53276184&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017014544(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by NuCana plc filed Critical NuCana plc
Publication of MX2017014544A publication Critical patent/MX2017014544A/es
Publication of MX374946B publication Critical patent/MX374946B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La invención provee NUC-1031 (gemcitabina-[fenil-benzoxi-L-alanini l])-fosfato), un derivado ProTide de gemcitabina, para usarse para hacer blanco en las células madre de cáncer; esta acción de hacer blanco en las células madre de cáncer se puede usar en la prevención o tratamiento del cáncer; la invención también provee NUC-1031 para usarse en el tratamiento de la recidiva de cáncer o cáncer refractario en un paciente humano; sin desear limitarse por hipótesis alguna, se cree que la capacidad de NUC-1031 para hacer blanco en las células madre de cáncer contribuye a su utilidad en el tratamiento de la recidiva de cáncer refractario.
MX2017014544A 2015-05-14 2015-05-14 Nuc-1031 (gemcitabina-[fenil-benzoxi-l-alaninil)]-fosfato) para usarse en el tratamiento de cáncer para hacer blanco en las células de cáncer. MX374946B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2015/051438 WO2016181093A1 (en) 2015-05-14 2015-05-14 Cancer treatments

Publications (2)

Publication Number Publication Date
MX2017014544A true MX2017014544A (es) 2018-09-26
MX374946B MX374946B (es) 2025-03-06

Family

ID=53276184

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017014544A MX374946B (es) 2015-05-14 2015-05-14 Nuc-1031 (gemcitabina-[fenil-benzoxi-l-alaninil)]-fosfato) para usarse en el tratamiento de cáncer para hacer blanco en las células de cáncer.
MX2020009154A MX390506B (es) 2015-05-14 2015-05-14 Nuc-1031 (gemcitabina-[fenil-benzoxi-l-alaninil])-fosfato) para usarse en el tratamiento neoadyuvante y adyuvante en pacientes con cáncer.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020009154A MX390506B (es) 2015-05-14 2015-05-14 Nuc-1031 (gemcitabina-[fenil-benzoxi-l-alaninil])-fosfato) para usarse en el tratamiento neoadyuvante y adyuvante en pacientes con cáncer.

Country Status (26)

Country Link
US (3) US20180289733A1 (es)
EP (2) EP3415149A1 (es)
JP (1) JP6761852B2 (es)
KR (1) KR20180021697A (es)
CN (2) CN115837028A (es)
AU (2) AU2015394135B2 (es)
BR (1) BR112017024461B1 (es)
CA (1) CA2985540C (es)
CY (1) CY1120516T1 (es)
DK (1) DK3197456T3 (es)
EA (1) EA201792509A1 (es)
ES (1) ES2668377T3 (es)
HR (1) HRP20180762T1 (es)
HU (1) HUE038541T2 (es)
IL (1) IL255591B (es)
LT (1) LT3197456T (es)
MX (2) MX374946B (es)
MY (1) MY192081A (es)
PH (1) PH12017502086B1 (es)
PL (1) PL3197456T3 (es)
PT (1) PT3197456T (es)
RS (1) RS57371B1 (es)
SI (1) SI3197456T1 (es)
SM (1) SMT201800303T1 (es)
TR (1) TR201806642T4 (es)
WO (1) WO2016181093A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
DK3447061T3 (da) 2011-03-01 2022-01-03 NuCana plc Farmaceutisk formulering omfattende et phosphoramidatderivat af 5-fluor-2'-deoxyuridin til anvendelse i cancerbehandling
HUE044605T2 (hu) 2012-11-16 2019-11-28 Univ College Cardiff Consultants Ltd RP/SP gemcitabin-[fenil-(benziloxi-L-alaninil)]-foszfát keveréke
KR102563040B1 (ko) 2014-06-25 2023-08-02 뉴카나 피엘씨 젬시타빈 전구 약물
PT3119794T (pt) 2014-06-25 2018-01-15 Nucana Biomed Ltd Formulação que compreende um pró-fármaco de gemcitabina
GB201417644D0 (en) 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
CN111909231B (zh) 2014-11-28 2025-10-17 努卡那有限公司 作为抗癌化合物的新的2’和/或5’-氨基酸酯氨基磷酸酯3’-脱氧腺苷衍生物
EP3353201B1 (en) 2015-09-25 2021-09-08 F. Hoffmann-La Roche AG Recombinant immunoglobulin heavy chains comprising a sortase conjugation loop and conjugates thereof
CA2994502C (en) 2015-10-05 2023-08-01 NuCana plc Combination therapy comprising nuc-1031 and carboplatin for cancer treatment
SMT202100665T1 (it) 2015-12-11 2022-03-21 NuCana plc Sintesi diastereoselettiva di derivati di fosfato e del profarmaco di gemcitabina nuc-1031
GB201522771D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative
WO2017109444A1 (en) * 2015-12-23 2017-06-29 Nucana Biomed Limited Combination therapy
AU2016375861B2 (en) * 2015-12-23 2021-12-23 NuCana plc Combination therapy
GB201609600D0 (en) * 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
GB201713916D0 (en) * 2017-08-30 2017-10-11 Nucana Biomed Ltd Treatment regimens
WO2020077353A2 (en) * 2018-10-12 2020-04-16 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for reducing cancer stem cells
CN117462555B (zh) * 2021-01-31 2025-12-30 兰州大学 6-巯基鸟嘌呤在制备预防和/或治疗酒精性胃溃疡药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317009D0 (en) * 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
CN104586832B (zh) * 2007-09-10 2018-02-16 北京强新生物科技有限公司 用于癌症治疗的组合物和方法
EP2274617A4 (en) * 2008-04-10 2011-11-09 Massachusetts Inst Technology METHOD OF DETECTING AND USING MEDIUM-TREATMENT AID ON CANCER STEM CELLS

Also Published As

Publication number Publication date
BR112017024461B1 (pt) 2023-04-04
AU2015394135B2 (en) 2021-09-16
MX390506B (es) 2025-03-20
EP3415149A1 (en) 2018-12-19
EP3197456B2 (en) 2023-10-11
EP3197456B1 (en) 2018-04-04
JP6761852B2 (ja) 2020-09-30
HRP20180762T1 (hr) 2018-08-24
PH12017502086B1 (en) 2022-12-09
EP3197456A1 (en) 2017-08-02
MX2020009154A (es) 2022-03-08
ES2668377T3 (es) 2018-05-17
DK3197456T3 (en) 2018-06-06
AU2015394135A1 (en) 2017-12-14
US20180289733A1 (en) 2018-10-11
IL255591B (en) 2021-10-31
HUE038541T2 (hu) 2018-10-29
JP2018515618A (ja) 2018-06-14
US20230226092A1 (en) 2023-07-20
CA2985540C (en) 2021-08-24
EA201792509A1 (ru) 2018-05-31
CA2985540A1 (en) 2016-11-17
CY1120516T1 (el) 2019-07-10
CN107835687A (zh) 2018-03-23
MX374946B (es) 2025-03-06
PL3197456T3 (pl) 2018-09-28
BR112017024461A2 (pt) 2018-07-24
AU2021277614A1 (en) 2021-12-23
PT3197456T (pt) 2018-05-22
SMT201800303T1 (it) 2018-07-17
CN115837028A (zh) 2023-03-24
MY192081A (en) 2022-07-26
US20210100825A1 (en) 2021-04-08
SI3197456T1 (en) 2018-08-31
RS57371B1 (sr) 2018-08-31
IL255591A (en) 2018-01-31
PH12017502086A1 (en) 2018-04-30
WO2016181093A1 (en) 2016-11-17
TR201806642T4 (tr) 2018-06-21
LT3197456T (lt) 2018-07-10
KR20180021697A (ko) 2018-03-05

Similar Documents

Publication Publication Date Title
MX374946B (es) Nuc-1031 (gemcitabina-[fenil-benzoxi-l-alaninil)]-fosfato) para usarse en el tratamiento de cáncer para hacer blanco en las células de cáncer.
CL2018003213A1 (es) Inhibidores enzimáticos.
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
CL2018000198A1 (es) Composiciones de arni de transtiretina (ttr) y métodos para su uso para el tratamiento o prevencion de enfermedades asociadas con ttr
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
PE20180243A1 (es) Composiciones que comprenden cepas bacterianas
BR112017002332A2 (pt) terapia de combinação para o tratamento de um paramixovírus
CO2018010504A2 (es) Inhibidores del enlace proteína-proteína de wdr5
UY36550A (es) Oligómeros antisentido de tau y sus usos
MX373103B (es) Ciclopropilaminas como inhibidores de desmetilasa específica de lisina 1 (lsd1).
EA201790737A1 (ru) Комбинированная терапия
NZ724343A (en) 4’-substituted nucleoside-derivatives as hiv reverse transcriptase inhibitors
MX383484B (es) Método para tratar el cáncer.
MX387283B (es) Tratamiento del cancer con tg02.
PE20180260A1 (es) Metodos y kits para tratar la depresion
MX375716B (es) Método para tratar adenocarcinoma de pulmón.
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
MX385138B (es) Inmunomoduladores de aminoacilindazol para el tratamiento de enfermedades autoinmunes.
BR112017009552A8 (pt) Métodos para alvejar o controle transcricional em regiões de super-realçador
AU2015267099A8 (en) Use of eribulin in the treatment of cancer
BR112017007715A2 (pt) derivados de tienopirimidina como inibidores de nik
CL2017003133A1 (es) Uso de derivados de bencimidazol para escape ácido nocturno
CL2020001888A1 (es) Terapia de combinación para tratar o prevenir el cáncer.
CL2019003084A1 (es) Tratamiento de cólicos infantiles.
MX2018015208A (es) Andrografolido para tratar formas progresivas de esclerosis multiple.

Legal Events

Date Code Title Description
FG Grant or registration